Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Help & Advice
University of Warwick

The Library

  • Login
  • Admin

Hydroxymethylglutaryl-CoA reductase inhibition with simvastatin in acute lung injury to reduce pulmonary dysfunction (HARP-2) trial : study protocol for a randomized controlled trial

Tools
- Tools
+ Tools

Irish Critical Care Trials Group (Including: McAuley, Daniel F., Laffey, John G., O'Kane, Cecilia M., Cross, L. J. Mark, Perkins, Gavin D., Murphy, Lynn, McNally, Christine, Crealey, Grainne and Stevenson, Michael). (2012) Hydroxymethylglutaryl-CoA reductase inhibition with simvastatin in acute lung injury to reduce pulmonary dysfunction (HARP-2) trial : study protocol for a randomized controlled trial. Trials, Vol.13 (No.1). p. 170. doi:10.1186/1745-6215-13-170 ISSN 1745-6215.

[img]
Preview
Text
WRAP_Perkins_1745-6215-13-170.pdf

Download (1080Kb) | Preview
Official URL: http://dx.doi.org/10.1186/1745-6215-13-170

Request Changes to record.

Abstract

Acute lung injury (ALI) is a common devastating clinical syndrome characterized by life-threatening respiratory failure requiring mechanical ventilation and multiple organ failure. There are in vitro, animal studies and pre-clinical data suggesting that statins may be beneficial in ALI. The Hydroxymethylglutaryl-CoA reductase inhibition with simvastatin in Acute lung injury to Reduce Pulmonary dysfunction (HARP-2) trial is a multicenter, prospective, randomized, allocation concealed, double-blind, placebo-controlled clinical trial which aims to test the hypothesis that treatment with simvastatin will improve clinical outcomes in patients with ALI.

Item Type: Journal Article
Subjects: R Medicine > RC Internal medicine
Divisions: Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Health Sciences
Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School
Library of Congress Subject Headings (LCSH): Lungs -- Wounds and injuries -- Treatment, Statins (Cardiovascular agents)
Journal or Publication Title: Trials
Publisher: Biomed Central
ISSN: 1745-6215
Official Date: 2012
Dates:
DateEvent
2012Published
Volume: Vol.13
Number: No.1
Page Range: p. 170
DOI: 10.1186/1745-6215-13-170
Status: Peer Reviewed
Publication Status: Published
Access rights to Published version: Open Access (Creative Commons)
Funder: Medical Research Council (Great Britain) (MRC), National Institute for Health Research (Great Britain) (NIHR), Scotland. Chief Scientist Office, National Institute for Social Care and Health Research (Wales) (NISCHR), Northern Ireland. Public Health Agency. HSC Research & Development Division, Ireland. Health Research Board, Intensive Care Society of Ireland
Grant number: HRA_POR/2010/131 (HRB)

Request changes or add full text files to a record

Repository staff actions (login required)

View Item View Item

Downloads

Downloads per month over past year

View more statistics

twitter

Email us: wrap@warwick.ac.uk
Contact Details
About Us